Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts - Marfella, Raffaele; D'Onofrio, Nunzia; Trotta, Maria Consiglia; Sardu, Celestino; Scisciola, Lucia; Amarelli, Cristiano; Balestrieri, Maria Luisa; Grimaldi, Vincenzo; Mansueto, Gelsomina; Esposito, Salvatore; D'Amico, Michele; Golino, Paolo; et al. (Metabolism, clinical and experimental, 2022)
Keywords: Adult; Biopsy; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - surgery; Diabetic Cardiomyopathies - drug therapy; Diabetic Cardiomyopathies - genetics; Diabetic Cardiomyopathies - physiopathology; Diabetic Cardiomyopathies - surgery; Diabetic cardiomyopathy; Female; Follow-Up Studies; Gene Expression - drug effects; Heart - drug effects; Heart - physiology; Heart Transplantation; Humans; JunD; Lipid Metabolism - drug effects; Male; Middle Aged; Myocardium - metabolism; Myocardium - pathology; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Proto-Oncogene Proteins c-jun - genetics; Proto-Oncogene Proteins c-jun - metabolism; SGLT2i; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; JunD; IRS-2; IRS-1; IVS; HIF-1α; AP-1; HTX; ISHLT; HOMA-IR; DSA; RT-PCR; Diabetic cardiomyopathy; EMB; ALCOA; SGLT2i; PPAR-γ